ArticleDiscover oncology2026
Prognostic implications and precision selection criteria of primary tumor resection in metastatic gallbladder adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder cancer is recognized as one of the most aggressive malignancies within the biliary system. Usually, the substantial part of patients are diagnosed at advanced stages, often with metastases to distant organs. In cases of metastatic gallbladder adenocarcinoma, the potential benefit of primary tumor resection (PTR) in improving patient prognosis remains an unresolved issue that warrants further investigation. PATIENTS AND
methodsWe collected data to identify patients diagnosed with gallbladder cancer and concurrent metastases to the liver, lungs, bones, brain, or distant lymph nodes between 2004 and 2021 from the Surveillance, Epidemiology, and End Results (SEER) database. The impact of primary tumor resection (PTR) on overall survival (OS) and cancer-specific survival (CSS) was evaluated using the Cox proportional hazards model. Kaplan-Meier survival curves were generated for additional clarity. Subgroup analyses were also conducted to identify patient groups that might have a longer survival period from PTR.
resultsA total of 1968 patients diagnosed with metastatic gallbladder adenocarcinoma at the time of initial presentation between 2004 and 2021 were included in the analysis. Among these, liver metastasis was the most frequent site of metastasis (n = 1695, 86.12%). Of the total cohort, 600 patients (30.49%) underwent PTR, and these patients demonstrated a significant improvement in both OS (0.679 [0.612-0.752], P < 0.001) and CSS (0.690 [0.619-0.768], P < 0.001). Notably, PTR was associated with reduced overall mortality in patients with isolated liver or distant lymph node metastases (liver metastasis: 0.690 [0.612-0.778], P < 0.001; distant lymph node metastasis: 0.498 [0.324-0.763], P < 0.001), as well as reduced cancer-specific mortality (liver metastasis: 0.698 [0.616-0.791], P < 0.001; distant lymph node metastasis: 0.522 [0.332-0.820], P = 0.003). In addition, patients with one or two metastatic organs who underwent PTR experienced a similar reduction in both overall mortality (1 metastatic organ: 0.691 [0.619-0.771], P < 0.001; 2 metastatic organs: 0.623 [0.434-0.895], P = 0.005) and cancer-specific mortality (1 metastatic organ: 0.700 [0.624-0.785], P < 0.001; 2 metastatic organs: 0.643 [0.439-0.940], P = 0.013).
conclusionThese results demonstrate that primary tumor resection (PTR) may prolong life expectancy of patients with certain subtypes of metastatic gallbladder adenocarcinoma. Consequently, these findings offer valuable insights and guidance for the management of metastatic gallbladder adenocarcinoma, particularly in selecting patients who may benefit from surgical intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.